Date: 2017-01-26
Type of information: Subvention
Company: Theradiag (France) PIoneer Project
Investors: European Eurostars Programme (EU)
Amount: €1.3 million
Funding type: grant
Planned used: The funds will support Theradiag's PIONEER collaborative project . The purpose of the project is to develop two tests based on circulating microRNA biomarkers and tissue messenger RNA (mRNA) in rectal cancer. Given the lack of any major breakthrough in this field, the aim of the PIONEER project is to improve clinical practices and enable a better evaluation of the response to preoperative chemoradiotherapy treatment, in order to apply the best therapeutic choice for the patient and thus increase their chances of entering remission. Theradiag, Asan Medical Center, the largest academic hospital in Korea, and CbsBioscience have joined forces via their complementary fields of expertise in order to develop an innovative solution combining two tests, one based on the signature of circulating microRNA biomarkers, the other on the identification of tissue mRNA markers. The Eurostars' grant will help validate specific new markers via the recruitment of a cohort of more than 300 patients.
Others: • On January 26, 2017, Theradiag announced that the company has been selected by the Eurostars-2 program to receive financial support for its PIONEER collaborative project undertaken by its Prestizia molecular biology platform and its South Korean partners, Professor Chang-sik Yu and his team at Asan Medical Center and CbsBioscience. This €2.2 million 3-year project will be partly funded by the Eurostars program. The total subsidy represents €1.3 million, approximately €300,000 of it for Theradiag. A consortium agreement between the 3 partners will be signed in the coming weeks.
Therapeutic area: Cancer - Oncology - Diagnostic
